Industry Symposia
Industry Symposium
Treatment-Resistant Schizophrenia (TRS): will new biological findings lead to novel drug development?
Chair
Peter Falkai, MD
Ludwig Maximilian University of Munich, Germany
Programme
Treatment-resistant schizophrenia (TRS): no progress in almost 40 years
P. Falkai, MD
Ludwig Maximilian University of Munich, Germany
R. Reddy, MD
Help Hospital, Vijayawada, India
C. Andrade, MD
National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India
C. Correll, MD
The Zucker Hillside Hospital, Zucker School of Medicine at Hofstra/Northwell, New York, USA; Charité University Medicine Berlin, Germany
Glutamate modulation by evenamide: clinically meaningful benefits and the ENIGMA-TRS phase 3 program
R. Anand, MD
Newron Pharmaceuticals
Q&A and Discussion
